Literature DB >> 11861063

Biological assays for interferons.

Anthony Meager1.   

Abstract

Interferons (IFN) are potent biologically active proteins synthesised and secreted by somatic cells of all mammalian species. They have been well characterised, especially those of human origin, with respect to structure, biological activities, and clinical therapeutic effects. While structural differences are known to exist among the IFN species that constitute the "IFN family" and despite the existence of different receptors for type I and type II IFN, all species have been shown to exert a similar spectrum of in vitro biological activities in responsive cells. Principal among the biological activities induced by IFN is antiviral activity, the activity used to originally define IFN. Antiviral activity of IFN is mediated via cell receptors and is dependent on the activation of signalling pathways, the expression of specific gene products, and the development of antiviral mechanisms. Sensitivity of cells to IFN-mediated antiviral activity is variable, and depends on a number of factors including cell type, expression of IFN receptors and downstream effector response elements, effectiveness of antiviral mechanisms, and the type of virus used to infect cells. Nevertheless, by the judicious use of sensitive cell lines in combination with appropriate cytopathic viruses, effective assays to measure the antiviral activity have been developed. Historically, "antiviral assays" (AVA) were the first type of biological assays that were developed to measure the relative activity or potency of IFN preparations. However, the subsequent discoveries of several other biological activities of IFN has opened the way to the development of assays based on one or other of these activities. The latter include inhibition of cell proliferation, regulation of functional cellular activities, regulation of cellular differentiation and immunomodulation. More recently, the cloning of IFN responsive genes has led to the development of "reporter gene assays". In this case, the promoter region of IFN responsive genes is linked with a heterologous reporter gene, for example, firefly luciferase or alkaline phosphatase, and transfected into an IFN-sensitive cell line. Stably transfected cell lines exposed to IFN increase expression of the reporter gene product in direct relation to the dose of IFN, the readout being a measure of this product's enzymic action. The current review aims to give a critical overview of the development, specificity, standardisation and present use of the various biological assay methods now available for the quantification of IFN activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11861063     DOI: 10.1016/s0022-1759(01)00570-1

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  25 in total

1.  In vivo bioluminescence imaging of cell differentiation in biomaterials: a platform for scaffold development.

Authors:  Juli R Bagó; Elisabeth Aguilar; Maria Alieva; Carolina Soler-Botija; Olaia F Vila; Silvia Claros; José A Andrades; José Becerra; Nuria Rubio; Jerónimo Blanco
Journal:  Tissue Eng Part A       Date:  2012-12-21       Impact factor: 3.845

2.  Species-independent bioassay for sensitive quantification of antiviral type I interferons.

Authors:  Thomas Kuri; Matthias Habjan; Nicola Penski; Friedemann Weber
Journal:  Virol J       Date:  2010-02-26       Impact factor: 4.099

3.  Characterization of bovine interferon α1: expression in yeast Pichia pastoris, biological activities, and physicochemical characteristics.

Authors:  Jianwei Shao; Chong Cao; Jun Bao; Hongtao Liu; Tongquan Peng; Mingchun Gao; Junwei Wang
Journal:  J Interferon Cytokine Res       Date:  2014-10-24       Impact factor: 2.607

4.  Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways.

Authors:  Justin C Paglino; Anthony N van den Pol
Journal:  J Virol       Date:  2011-07-06       Impact factor: 5.103

5.  Interferon-β sensitivity of tumor cells correlates with poor response to VA7 virotherapy in mouse glioma models.

Authors:  Janne Ruotsalainen; Miika Martikainen; Minna Niittykoski; Tuulia Huhtala; Tytti Aaltonen; Jari Heikkilä; John Bell; Markus Vähä-Koskela; Ari Hinkkanen
Journal:  Mol Ther       Date:  2012-03-20       Impact factor: 11.454

6.  Overproduction of double-stranded RNA in vesicular stomatitis virus-infected cells activates a constitutive cell-type-specific antiviral response.

Authors:  Derek Ostertag; Traci M Hoblitzell-Ostertag; Jacques Perrault
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

7.  Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.

Authors:  Anne Boulestin; Nassim Kamar; Florence Legrand-Abravanel; Karine Sandres-Saune; Laurent Alric; Jean-Pierre Vinel; Lionel Rostaing; Jacques Izopet
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Antiviral activity of limitin against encephalomyocarditis virus, herpes simplex virus, and mouse hepatitis virus: diverse requirements by limitin and alpha interferon for interferon regulatory factor 1.

Authors:  Shin-Ichiro Kawamoto; Kenji Oritani; Hideo Asada; Isao Takahashi; Jun Ishikawa; Hitoshi Yoshida; Masahide Yamada; Naoko Ishida; Hidetoshi Ujiie; Hiroaki Masaie; Yoshiaki Tomiyama; Yuji Matsuzawa
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

9.  Enhancement of reporter gene detection sensitivity by insertion of specific mini-peptide-coding sequences.

Authors:  J Cutrera; D Dibra; X Xia; S Li
Journal:  Cancer Gene Ther       Date:  2009-08-28       Impact factor: 5.987

10.  Attenuating mutations in nsP1 reveal tissue-specific mechanisms for control of Ross River virus infection.

Authors:  Kristina A Stoermer Burrack; David W Hawman; Henri J Jupille; Lauren Oko; Marissa Minor; Katherine D Shives; Bronwyn M Gunn; Kristin M Long; Thomas E Morrison
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.